<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590720</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP143</org_study_id>
    <nct_id>NCT00590720</nct_id>
  </id_info>
  <brief_title>A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma</brief_title>
  <official_title>A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the safety and tolerability of multiple fixed
      doses of MEDI-528 in adult patients with stable asthma and exercise-induced
      bronchoconstriction (EIB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of multiple
      fixed escalating SC doses of MEDI-528 in adult patients with stable asthma and
      exercise-induced bronchoconstriction (EIB).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study is replaced by MI-CP198 per CPM.
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Days 0 - 150</time_frame>
    <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Days 0 - 150</time_frame>
    <description>Number of participants experiencing serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</measure>
    <time_frame>Days 0, 28, 56, 119, and 150</time_frame>
    <description>Number of participants with ADA to MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 measured before and after exercising on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 before and after exercise on Day 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 before and after exercise on Day 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>AUC of FEV1 at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>AUC of FEV1 at Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>AUC of FEV1 at Day 150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after 30 minues of exercise on Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after exercise on Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
    <description>Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after exercise on Day 150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Trough Concentration (Cmin)</measure>
    <time_frame>Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150</time_frame>
    <description>Cmin of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Trough Concentration at Last Measurable Time Point (Cmin_last)</measure>
    <time_frame>Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150</time_frame>
    <description>Cmin_last of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150</time_frame>
    <description>T1/2 of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index</measure>
    <time_frame>Days 0 and 24</time_frame>
    <description>Ratio of trough concentrations after first (Day 0) and last (Day 24) dose of MEDI-528</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MEDI528 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI528 50 mg</intervention_name>
    <description>MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
    <arm_group_label>MEDI528 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must meet all of the following criteria:

          -  Male or female adults, age 18 through 50 years at the time of screening;

          -  Weight 50-100 kg and body mass index ≤ 35;

          -  Written informed consent obtained from the patient prior to receipt of any study
             medication or beginning study procedures;

          -  Documented clinical history of asthma and receiving stable treatment for ≥ 1 month
             prior to Study Day 0;

          -  Airway hyperresponsiveness (AHR) on methacholine inhalation challenge testing at
             screening (or a documented history within the past 6 months), with provoking
             concentration of methacholine to cause a 20% fall in FEV1(subscript) (PC20) ≤ 8 mg/mL
             (Crapo, 2000);

          -  Exercise-induced bronchoconstriction (EIB) with a decrease in FEV1 (subscript) of ≥
             15% from pre-exercise challenge testing level at screening;

          -  Able to provide spirometry readings that meet American Thoracic Society (ATS) and
             European Respiratory Society (ERS) standards (Miller, 2005);

          -  Women of childbearing potential, unless surgically sterile or at least 1 year
             post-menopausal, must use two effective methods of avoiding pregnancy (including oral,
             transdermal, or implanted contraceptives, intrauterine device, female condom,
             spermicide, diaphragm, cervical cap, abstinence, contraceptive foam, or use of a
             condom by the sexual partner or sterile sexual partner) from screening through Study
             Day 0, and must agree to continue using such precautions through Study Day 150.
             Cessation of birth control after this point should be discussed with a responsible
             physician. Men, unless surgically sterile, must likewise use an effective method of
             birth control (condom with spermicide) and must agree to continue using such
             precautions from screening through Study Day 150;

          -  Able to complete the study period, including follow-up period, of up to approximately
             150 days; and

          -  Willing to forego other forms of experimental treatment and study procedures during
             the study and for 30 days after the follow-up period is completed.

        Exclusion Criteria:

        Patients must have none of the following criteria:

          -  Receipt of MEDI-528 in any previous clinical study;

          -  History of allergy or reaction to any component of the study drug formulation;

          -  Lung disease other than asthma (eg, chronic obstructive pulmonary disease, cystic
             fibrosis);

          -  Forced expiratory volume in 1 second (FEV1-subscript) &lt; 70% of predicted values at
             screening;

          -  Use of systemic immunosuppressive drugs including systemic corticosteroids, ICS with
             doses &gt; 800 μg/day budesonide (or another ICS of equivalent dose), long-acting β2
             agonists, cromolyn sodium, nedocromil sodium, leukotriene receptor antagonists,
             theophylline, or omalizumab from screening through Study Day 150;

          -  Current use of any β-adrenergic antagonist (eg, propranolol);

          -  Any disease or illness, other than asthma, that is likely to require the use of
             systemic corticosteroids during the study period;

          -  Acute illnesses or evidence of significant active infection, such as fever ≥ 38.0°C
             (100.5°F) from screening through Study Day 0;

          -  Current allergy vaccination therapy (desensitization immunotherapy);

          -  Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5
             half-lives of the agent prior to screening;

          -  Pregnancy (women of child bearing potential, unless surgically sterile or at least 1
             year postmenopausal, must have a negative serum and urine pregnancy test at screening
             before methacholine inhalation challenge testing and a negative urine pregnancy test
             prior to study drug administration on Study Day 0);

          -  Breastfeeding or lactating woman;

          -  Evidence of infection with hepatitis B or C virus or HIV-1 or HIV-2, or active
             infection with hepatitis A; must have negative HIV-1, HIV-2, hepatitis A, B, and C
             tests at screening;

          -  History of cancer other than basal cell carcinoma of the skin or cervical
             carcinoma-in-situ treated with apparent success with curative therapy more than 1 year
             prior to Study Day 0;

          -  History of primary immunodeficiency

          -  History of pancreatitis or currently active gastroduodenal ulcer;

          -  Current use of tobacco products or a history of use of tobacco products of more than
             one cigarette per month or equivalent within 1 year prior to randomization or history
             of smoking of ≥ 10 pack-years;

          -  History of life-long urinary retention;

          -  History of anaphylaxis (defined as immediate life-threatening event requiring medical
             invention);

          -  Elective surgery planned from screening through Study Day 150;

          -  Clinically significant abnormality, as determined by the investigator, on 12-lead ECG
             or chest radiograph at screening;

          -  History of any disease, evidence of any current disease (other than asthma), any
             finding upon physical examination, or any laboratory abnormality, that, in the opinion
             of the investigator or medical monitor, may compromise the safety of the patient in
             the study or confound the analysis of the study; or

          -  Any employee of the research site who is involved with the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Parker, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Healthcare Assessment, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterbury Pulmonary Associates</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of South Florida, Asthma, Allergy &amp; Immunology Clinical Research Unit</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze,Wheeze &amp; Itch Associates, LLC</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Medical Research Associates, Inc</name>
      <address>
        <city>No. Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center, LLC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calgary COPD &amp; Asthma Program</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHN- Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Appliquee en Allergie de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <results_first_submitted>October 22, 2013</results_first_submitted>
  <results_first_submitted_qc>February 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 21, 2014</results_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Bronchitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 11 subjects participated in this study from 26Feb2008 to 27Dec2008 at 4 sites in the United States of America.</recruitment_details>
      <pre_assignment_details>Treatment assignments were determined using a block randomization procedure with a 2:1 ratio (MEDI-528:placebo) via an interactive voice response system on Day 0 before study drug administration.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PLACEBO</title>
          <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>MEDI528 50 mg</title>
          <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PLACEBO</title>
          <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>MEDI528 50 mg</title>
          <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="13.5"/>
                    <measurement group_id="B2" value="32.1" spread="8.2"/>
                    <measurement group_id="B3" value="32.0" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
        <time_frame>Days 0 - 150</time_frame>
        <population>All participants who received at least one dose of investigational product (MEDI-528 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
          <population>All participants who received at least one dose of investigational product (MEDI-528 or placebo).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>Number of participants experiencing serious adverse events</description>
        <time_frame>Days 0 - 150</time_frame>
        <population>All participants who received at least one dose of investigational product (MEDI-528 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>Number of participants experiencing serious adverse events</description>
          <population>All participants who received at least one dose of investigational product (MEDI-528 or placebo).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</title>
        <description>Number of participants with ADA to MEDI-528</description>
        <time_frame>Days 0, 28, 56, 119, and 150</time_frame>
        <population>All participants who received at least one dose of MEDI-528.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</title>
          <description>Number of participants with ADA to MEDI-528</description>
          <population>All participants who received at least one dose of MEDI-528.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 measured before and after exercising on Day 28.</description>
        <time_frame>Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and performed acceptable spirometry (n=9, with 2 placebo and 7 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 measured before and after exercising on Day 28.</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and performed acceptable spirometry (n=9, with 2 placebo and 7 MEDI-528).</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.23"/>
                    <measurement group_id="O2" value="-0.21" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Two-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 before and after exercise on Day 56.</description>
        <time_frame>Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 before and after exercise on Day 56.</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.04"/>
                    <measurement group_id="O2" value="-0.02" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Two-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 before and after exercise on Day 150.</description>
        <time_frame>Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 before and after exercise on Day 150.</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.62"/>
                    <measurement group_id="O2" value="-0.13" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Two-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 28.</description>
        <time_frame>Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and performed acceptable spirometry (n=9, 2 placebo and 7 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 28.</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and performed acceptable spirometry (n=9, 2 placebo and 7 MEDI-528).</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="1.53"/>
                    <measurement group_id="O2" value="-6.49" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Two-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 56.</description>
        <time_frame>Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 56.</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.1" spread="7.41"/>
                    <measurement group_id="O2" value="-1.01" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Two-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 150.</description>
        <time_frame>Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 150.</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2" spread="15.48"/>
                    <measurement group_id="O2" value="-5.04" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Two-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>AUC of FEV1 at Day 28</description>
        <time_frame>Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>AUC of FEV1 at Day 28</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
          <units>Liter x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.69" spread="41.14"/>
                    <measurement group_id="O2" value="86.04" spread="15.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>AUC of FEV1 at Day 56</description>
        <time_frame>Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=7, 2 placebo and 5 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>AUC of FEV1 at Day 56</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=7, 2 placebo and 5 MEDI-528).</population>
          <units>Liter x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.38" spread="44.72"/>
                    <measurement group_id="O2" value="83.35" spread="22.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>AUC of FEV1 at Day 150</description>
        <time_frame>Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=7, 2 placebo and 5 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>AUC of FEV1 at Day 150</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=7, 2 placebo and 5 MEDI-528).</population>
          <units>Liter x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.53" spread="18.31"/>
                    <measurement group_id="O2" value="81.37" spread="19.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after 30 minues of exercise on Day 28</description>
        <time_frame>Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=9, 2 placebo and 7 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after 30 minues of exercise on Day 28</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=9, 2 placebo and 7 MEDI-528).</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="0.00"/>
                    <measurement group_id="O2" value="5.71" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after exercise on Day 56</description>
        <time_frame>Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after exercise on Day 56</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="0.00"/>
                    <measurement group_id="O2" value="5.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after exercise on Day 150</description>
        <time_frame>Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)</time_frame>
        <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after exercise on Day 150</description>
          <population>All participants who received at least 4 doses of investigational product (MEDI-528 or placebo; n=10, 3 placebo and 7 MEDI-528) and had available data (n=8, 2 placebo and 6 MEDI-528).</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.50" spread="3.54"/>
                    <measurement group_id="O2" value="5.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Trough Concentration (Cmin)</title>
        <description>Cmin of MEDI-528</description>
        <time_frame>Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150</time_frame>
        <population>All participants who received at least one dose of MEDI-528.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Trough Concentration (Cmin)</title>
          <description>Cmin of MEDI-528</description>
          <population>All participants who received at least one dose of MEDI-528.</population>
          <units>Microgram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.207" spread="1.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Trough Concentration at Last Measurable Time Point (Cmin_last)</title>
        <description>Cmin_last of MEDI-528</description>
        <time_frame>Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150</time_frame>
        <population>All participants who received at least one dose of MEDI-528.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Trough Concentration at Last Measurable Time Point (Cmin_last)</title>
          <description>Cmin_last of MEDI-528</description>
          <population>All participants who received at least one dose of MEDI-528.</population>
          <units>Microgram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="18.123" spread="10.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life (T1/2)</title>
        <description>T1/2 of MEDI-528</description>
        <time_frame>Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150</time_frame>
        <population>All participants who received at least one dose of MEDI-528.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (T1/2)</title>
          <description>T1/2 of MEDI-528</description>
          <population>All participants who received at least one dose of MEDI-528.</population>
          <units>Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="34.708" spread="7.891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Index</title>
        <description>Ratio of trough concentrations after first (Day 0) and last (Day 24) dose of MEDI-528</description>
        <time_frame>Days 0 and 24</time_frame>
        <population>All participants who received at least one dose of MEDI-528 (n=7) and had available data (n=5).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 50 mg</title>
            <description>MEDI528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Index</title>
          <description>Ratio of trough concentrations after first (Day 0) and last (Day 24) dose of MEDI-528</description>
          <population>All participants who received at least one dose of MEDI-528 (n=7) and had available data (n=5).</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7.615" spread="5.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PLACEBO</title>
        </group>
        <group group_id="E2">
          <title>MEDI528 50 mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nuclear magnetic resonance imaging abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bicarbonate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyposmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Parker, MD</name_or_title>
      <organization>MedImmune</organization>
      <phone>301-398-0000</phone>
      <email>parkerj@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

